WO2009150318A1 - Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation - Google Patents
Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation Download PDFInfo
- Publication number
- WO2009150318A1 WO2009150318A1 PCT/FR2009/000573 FR2009000573W WO2009150318A1 WO 2009150318 A1 WO2009150318 A1 WO 2009150318A1 FR 2009000573 W FR2009000573 W FR 2009000573W WO 2009150318 A1 WO2009150318 A1 WO 2009150318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkenyl
- formyl
- alkyl
- heteroaryl
- Prior art date
Links
- 0 *C1=Nc2ccccc2C2OC12 Chemical compound *C1=Nc2ccccc2C2OC12 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Definitions
- the subject of the invention is novel 2-substituted quinoline derivatives, a process for their preparation and their use for the production of medicaments.
- Quinolines substituted with various structures have been described for their action on the treatment of protozoal infections, such as leishmaniasis, trypanosomiasis, toxoplasmosis, and / or retrovirus infections such as HIV or HTLV. .
- a strategy sometimes used to discover new active ingredients consists of subjecting them to the action of the biological medium for which they are intended and then to identifying the metabolites formed. These are often very effective active ingredients.
- this approach has certain drawbacks: in vivo studies in animals pose ethical problems and the identification of metabolites in an organism, in sometimes very small amounts, is difficult. In vitro metabolism studies do not encounter ethical difficulties, but often these studies lead to such small quantities of products that their identification is difficult. The complexity of the reactions due to the presence of microorganisms in the medium does not make it possible to identify all the compounds likely to be of therapeutic interest because some are retransformed directly without being able to be identified.
- MEPs metallo porphyrins
- a first object of the invention is a process for producing molecules derived from 2-substituted quinolines, these molecules having in common to be metabolites or analogs of metabolites of 2-substituted quinolines.
- This process is characterized in that it comprises at least one step during which a molecule corresponding to the general formula (I) is reacted:
- R represents a group selected from: - a hydrogen atom, an alkyl group C 1 -C 5 alkenyl, C 2 to C 5 alkynyl, C 2 -C 15, a formyl group or a heteroaryl group, C 4 -C 8 the latter being optionally substituted by one or more hydroxyl groups; a C 1 -C 5 alkyl or C 2 -C 7 alkenyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl, carboxyl, C 7 -C 13 aryloxycarbonyl and alkyloxycarbonyl groups; C 2 to C 8 , C 3 to C 9 alkenyloxycarbonyl, cyano (CN), amine (NH 2 ), C 1 to C 7 alkoxy, phenoxy, C 3 to C 6 cycloalkyl, C 6 to C 12 aryl, heteroaryl C 4 to C 8, heteroaryloxy, C 4 -C 18 aryl s
- a C 2 to C 7 alkynyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl, carboxyl, C 7 to C 3 aryloxycarbonyl, C 2 to C 8 alkyloxycarbonyl and alkenyloxycarbonyl groups; C 3 to C 9 , cyano, C 6 to C 2 aryl, C 4 to C 8 heteroaryl, C 6 to C 2 arylsulfone, C 1 to C 7 alkylsulfone, C 1 to C 7 thioalkyl and C 1 to C 7 aminoalkyl 7 ;
- R is chosen from:
- a C 1 -C 8 alkyl or C 2 -C 7 alkenyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl, carboxyl, cyano (CN), amine (NH 2 ) groups;
- a C 2 to C 7 alkynyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl and carboxyl groups.
- R is chosen from: A C 2 -C 5 alkyl or alkenyl group, optionally carrying one or more functions chosen from: -OH, CN.
- the oxidizing agent is advantageously chosen from: H 2 O 2 , sodium hypochlorite, iodosylbenzene, chloroperbenzoic acid, tert-butyl hydroperoxide and 2,6-dichloropyridine N-oxide.
- the oxidizing agent is hydrogen peroxide H 2 O 2 , which is advantageously used at a concentration of 30 to 45% in solution in water.
- the reaction is carried out in a solvent or a mixture of solvents.
- the solvent is advantageously chosen from: water, acetonitrile, dichloromethane, chloroform, as well as their mixtures, and advantageously in a mixture of acetonitrile and dichloromethane.
- the reaction is carried out in the presence of H 2 O 2 and an imidazole cocatalyst in a solvent or a mixture of solvents composed of dichloromethane and acetonitrile.
- Other cocatalysts can also be used in place of imidazole to make the reaction more effective.
- pyridine histidine, triethylamine, 4-methylpyridine, 2,4,6-trimethylpyridine, N, N, N ', N'-tetramethylethylenediamine (TMDEA), N-methylmorpholine and 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU).
- the method of the invention provides access to the molecules of formula (II) (molecules (IIa), (Hb) and (IIc)) and (III) below:
- R ' represents a group chosen from:
- a C 2 to C 6 alkynyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl, carboxyl, C 7 to C 13 aryloxycarbonyl, C 2 to C 8 alkyloxycarbonyl, alkenyloxycarbonyl groups, C 3 to Cg, cyano, C 6 -C 12 heteroaryl, C 4 -C 18 aryl sulfone C 6 -C 12 alkylsulfone, C 1 -C 7 thioalkyl, C 1 -C 7 aminoalkyl C 1 at C 7 ; or a C 2 to C 4 alkenyl or alkynyl group substituted with at least one C 1 to C 7 trialkylsilyl group.
- R ' chosen from:
- a C 1 to C 7 alkyl or C 2 to C 6 alkenyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl, carboxyl, cyano (CN), amine (NH 2 ) groups; a C 2 -C 6 alkynyl group carrying at least one substituent chosen from oxygen, halogens and hydroxyl, formyl and carboxyl groups.
- R ' is chosen from the following groups: H, C 1 -C 4 alkyls and C 2 -C 4 alkenyls optionally bearing one or more functions chosen from: OH, CN.
- the molecules thus obtained are obtained with yields much higher than those which could be obtained by the biochemical processes of the prior art. In addition, these processes are easily extrapolated on an industrial scale. These molecules can thus be easily separated using methods well known to those skilled in the art such as liquid-liquid extraction and chromatography. They can therefore be obtained in isolated form.
- the usable MEPs can be defined by the formula below:
- M represents a metal atom selected from: Mn, Ni, Fe, Co, Mo. Cu;
- X represents a halogen atom: Cl, Br, I or an acetate group
- R 1 , R 2 which are identical or different, are chosen from halogen atoms: F, Cl, Br, I, methyl and methoxy groups.
- MEPs some are known (Lindsey JS et al., Tetrahedron Lett., 1986, 27, 4969, Ram Singh and Geetanjali, J. Braz, Chem Soc), in particular the two following MEPs are used preferentially for the implementation of of the invention:
- a metalloporphyrin chosen from: Fe (TDCPP) Cl, Fe (TPP) Cl, Fe (TPCFP) C1, Mn (TPP) C1.
- TPP tetraphenyl porphyrin
- TPCFP tetraphenyl chloro-fluoro porphyrin
- TDCPP tetra-dichlorophenyl porphyrin
- CH (CH 3 ) 2 are new and constitute another object of the invention.
- the molecules of formula (III) may be subjected to a hydrolysis treatment in an acidic medium which makes it possible to access the molecules of formula (V) according to the scheme below:
- the invention also relates to a process for preparing compounds of formula (V) in which R has the same definition as for formula (I). It also relates to the compounds of formula (V).
- the molecules of formula (V) may be subjected to an oxidation treatment which provides access to the molecules of formula (VI) and (VII) according to the scheme below:
- the subject of the invention is also a process for the preparation of compounds of formula (VI) and (VII) in which R has the same definition as for formula (I). It also relates to compounds of formula (VI) and (VII) in tautomeric equilibrium.
- the subject of the invention is also any pharmaceutical composition comprising a product of formula (IIa), (Hb), (IIc), (III), (IV), (V) or (VI) as defined above, and a pharmaceutical carrier, in particular with one or more non-toxic inert excipients adapted to the pathology, to the population to be treated and to climatic conditions.
- the invention particularly relates to any pharmaceutical composition comprising a product of formula 3b, 3c, 3d, 4a, 4b, 4c, 6a, 7a or 8a and a pharmaceutical carrier.
- compositions of the invention mention may be made of those which allow oral, parenteral, nasal administration, tablets (single or coated), sublingual tablets, capsules, lozenges, suppositories, creams, ointments, injectable preparations, oral suspensions etc.
- the dosage is adapted according to: the pathology to be treated, the severity of the condition, the age and weight of the patient, the route of administration. It can range from 0.01 to 50 mg per day in one or more doses.
- the subject of the invention is also a medicinal product comprising a molecule of formula (IIa), (Hb), (IIc), (III), (IV), (V) or (VI) as defined above, for use in the prevention or treatment of a disease selected from protozoal infections, such as leishmaniasis, trypanosomiasis, toxoplasmosis, and / or retrovirus infections such as HIV or HTLV .
- a disease selected from protozoal infections, such as leishmaniasis, trypanosomiasis, toxoplasmosis, and / or retrovirus infections such as HIV or HTLV .
- a solution composed of 1 g (5.88 mmol) of n-propyl-2-quinoline 2a, 40 mg (0.58 mmol) of imidazole and 133 mg of Mn (TPCFP) is initially prepared. Cl in a mixture of 20 ml CH 2 Cl 2 / acetonitrile (1/1, v / v). To the stirring mixture, another solution containing 200 mg (2.9 mmol) of imidazole and 3 ml of 35% H 2 O 2 (200 equivalents) in 26.5 ml of water was added dropwise over 1 hr. acetonitrile. The reaction medium is stirred at room temperature for 2 hours.
- IR 1 2960, 2925, 2855, 1725, 1580, 1275:
- IR cm- 1 2920, 2215, 1565, 1455, 970;
- IR cm- 1 2925, 2220, 1745, 1570, 1445, 960
- a tablet is prepared using the following ingredients:
- Compound 4a ethyl acetate, corn starch, microcrystalline cellulose, carnauba wax, titanium dioxide, ethanol, 2-ethoxyethanol, starchy sodium glycolate, ammonium hydroxide, hydroxypropylcellulose, hypromellose, shellac, black iron oxide , red iron oxide, polyethylene glycol, propylene glycol and magnesium stearate.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09761869A EP2291381A1 (fr) | 2008-05-20 | 2009-05-15 | Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation |
BRPI0908627A BRPI0908627A2 (pt) | 2008-05-20 | 2009-05-15 | processo para se produzir moléculas escolhidas entre as das fórmulas (iia), (iib), (iic) e (iii), molécula de fórmula (iia), (iib), (iic), (iii), (iv) e (v), processo para produzir uma molécula que corresponde à formula (v), (vi), ou (vii), moléculas, composição farmacêutica e uso de uma composição |
US12/993,102 US20120225903A1 (en) | 2008-05-20 | 2009-05-15 | Novel 2-Substituted Quinoline Derivatives, And Method For Preparing Same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0802745 | 2008-05-20 | ||
FR0802745A FR2931479B1 (fr) | 2008-05-20 | 2008-05-20 | Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009150318A1 true WO2009150318A1 (fr) | 2009-12-17 |
Family
ID=40149587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2009/000573 WO2009150318A1 (fr) | 2008-05-20 | 2009-05-15 | Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120225903A1 (fr) |
EP (1) | EP2291381A1 (fr) |
BR (1) | BRPI0908627A2 (fr) |
FR (1) | FR2931479B1 (fr) |
WO (1) | WO2009150318A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE282457C (fr) * | ||||
US4440771A (en) * | 1982-02-12 | 1984-04-03 | The United States Of America As Represented By The Secretary Of The Army | 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections |
WO1993007125A1 (fr) * | 1991-10-03 | 1993-04-15 | Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) | Quinoleines 2-substituees pour le traitement des leishmanioses |
WO2002057238A1 (fr) * | 2001-01-17 | 2002-07-25 | Institut De Recherche Pour Le Developpement (Ird) | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
WO2005087211A1 (fr) * | 2004-03-05 | 2005-09-22 | The Regents Of The University Of California | Composes antiparasitaires et leurs procedes d'utilisation |
-
2008
- 2008-05-20 FR FR0802745A patent/FR2931479B1/fr not_active Expired - Fee Related
-
2009
- 2009-05-15 WO PCT/FR2009/000573 patent/WO2009150318A1/fr active Application Filing
- 2009-05-15 EP EP09761869A patent/EP2291381A1/fr not_active Withdrawn
- 2009-05-15 US US12/993,102 patent/US20120225903A1/en not_active Abandoned
- 2009-05-15 BR BRPI0908627A patent/BRPI0908627A2/pt not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE282457C (fr) * | ||||
US4440771A (en) * | 1982-02-12 | 1984-04-03 | The United States Of America As Represented By The Secretary Of The Army | 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections |
WO1993007125A1 (fr) * | 1991-10-03 | 1993-04-15 | Institut Français De Recherche Scientifique Pour Le Developpement En Cooperation (Orstom) | Quinoleines 2-substituees pour le traitement des leishmanioses |
WO2002057238A1 (fr) * | 2001-01-17 | 2002-07-25 | Institut De Recherche Pour Le Developpement (Ird) | Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus |
WO2005087211A1 (fr) * | 2004-03-05 | 2005-09-22 | The Regents Of The University Of California | Composes antiparasitaires et leurs procedes d'utilisation |
Non-Patent Citations (16)
Title |
---|
A.WALKER ET AL: "1,2-di-(2-quinolyl)ethane and certain related compounds", JOURNAL OF ORGANIC CHEMISTRY, vol. 16, no. 11, 1951, pages 1805 - 1808, XP002517738 * |
AKAGAH, BERNARDIN ET AL: "Oxidation of antiparasitic 2-substituted quinolines using metalloporphyrin catalysts: scale-up of a biomimetic reaction for metabolite production of drug candidates", ORGANIC & BIOMOLECULAR CHEMISTRY , 6(24), 4494-4497 CODEN: OBCRAK; ISSN: 1477-0520, 2008, XP002517742 * |
CHEMICAL & PHARMACEUTICAL BULLETIN , 30(6), 2003-10 CODEN: CPBTAL; ISSN: 0009-2363, 1982 * |
D.R. BUSHMAN AND CO: "Solvolysis of the quinoline 5,6- and 7,8-oxides: Effects of the ring nitrogen", J. AM. CHEM. SOC., vol. 111, 1989, pages 2688 - 2691, XP002517734 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 5 March 2008 (2008-03-05), XP002517744, Database accession no. 10672833 (BRN) * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1982, YAMAMOTO, YUTAKA ET AL: "Studies on organometallic compounds. III. Reaction of trimethylstannylazines with acyl chlorides. A novel carbon-carbon bond formation of pyridine nuclei", XP002517746, retrieved from STN Database accession no. 1982:615946 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAMAZAKI, TAKAO ET AL: "The reactions of ethyl 2-quinolyl- and 2-pyridylcyanoacetate", XP002517745, retrieved from STN Database accession no. 1976:421052 * |
E.M.BUNNELLE ET AL: "Pt-catalyzed cyclisation/migration of propargylic alcohols for the synthesis of 3(2H)-furanones, pyrrolones,indolizines and indolizinones", TETRAHEDRON, vol. 64, no. 29, 5 March 2008 (2008-03-05), pages 7008 - 7014, XP002517739 * |
F.H. CASE ET AL: "The synthesis of certain alkyl- and phenyl-substituted 2,2'-biquinolines", J. AM.CHEM. SOC., vol. 75, no. 20, 1953, pages 4920 - 4921, XP002517737 * |
FONTANA, FRANCESCA ET AL: "Homolytic acylation of protonated pyridines and pyrazines with .alpha.-keto acids: the problem of monoacylation", JOURNAL OF ORGANIC CHEMISTRY , 56(8), 2866-9 CODEN: JOCEAH; ISSN: 0022-3263, 1991, XP002517741 * |
HETEROCYCLES , 4(4), 713-18 CODEN: HTCYAM; ISSN: 0385-5414, 1976 * |
NOMLAND, ASHLEY ET AL: "2-Quinolinecarboxaldehyde: an unusual partner in the Henry reaction and subsequent elimination", TETRAHEDRON LETTERS , 49(38), 5511-5514 CODEN: TELEAY; ISSN: 0040-4039, 2008, XP002517743 * |
R.JAIN ET AL: "A one step preparation of functionalized 3-cyano-2-pyridones", TETRAHEDRON LETTERS, vol. 36, no. 19, 1995, pages 3307 - 3310, XP002517740 * |
S.K. AGARWAL ET AL: "Arene oxides and trans-dihydrodiols of quinoline", TETRAHEDRON LETTERS, vol. 27, no. 36, 1986, pages 4253 - 4256, XP009113175 * |
S.V. TSUKERMAN ET AL: "Electronic absorption spectra of the cations and anions formed from pyrrole analogs of the chalcones", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 4, no. 5, 1971, pages 595 - 599, XP002517736, ISSN: 0009-3122 * |
S.V.TSUKERMAN ET AL: "Infrared spectra of quinoline analogs of chalcones", JOURNAL OF APPLIED SPECTROSCOPY, vol. 5, no. 4, 1966, new york, pages 365 - 371, XP009113174 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0908627A2 (pt) | 2015-09-15 |
FR2931479B1 (fr) | 2012-12-07 |
US20120225903A1 (en) | 2012-09-06 |
EP2291381A1 (fr) | 2011-03-09 |
FR2931479A1 (fr) | 2009-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1919474B1 (fr) | Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar | |
EP0684241B1 (fr) | N-pyridyl carboxamides et dérivés, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
EP2379501B1 (fr) | Procede de preparation d'esters actives | |
WO2004029036A1 (fr) | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates | |
EP0313458B1 (fr) | Nouveaux imidazo (2,1-b) benzothiazoles et leurs sels d'addition avec les acides, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant | |
FR2780404A1 (fr) | Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0452204A1 (fr) | Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP2291381A1 (fr) | Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation | |
EP1992619A1 (fr) | Procédé de préparation de 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles et produits intermédiaires utilisés dans ce procédé | |
EP0196943B1 (fr) | Nouveaux dérivés 8-thiotétrahydroquinoléines et leurs sels | |
EP1461319B1 (fr) | Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives | |
FR2801309A1 (fr) | Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0062580B1 (fr) | Dérivés de l'imidazo(1,2-a)quinoléines | |
EP0027412B1 (fr) | Dérivés de la pyridine, procédé pour leur préparation et médicaments les contenant | |
EP2516400B1 (fr) | Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique | |
EP0412898A1 (fr) | Nouveaux dérivés d'oxazolo pyridines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1050530B1 (fr) | 1-Aza-2-Alkyl-6-Aryl-Cycloalcanes utiles pour améliorer la mémoire | |
FR2846654A1 (fr) | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CN111018784B (zh) | 一种苯并氮杂卓类化合物的制备方法 | |
EP0261004A2 (fr) | Nouveaux dérivés de l'imidazole et leurs sels, leur procédé de préparation, leur application comme médicaments et les compositions les renfermant | |
FR2541680A1 (fr) | Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent | |
CA2393951C (fr) | Procede de preparation de quinoleine-5,8-diones | |
EP0293294A2 (fr) | Nouvelles imidazo /1,2-a/ pyrimidines et leurs sels, leur procédé et les intermédiaires de préparation, l'application à titre de médicaments et les compositions les renfermant | |
CA2634320A1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0695747A1 (fr) | Dérivés N-oxydes de 1-(7-chloroquinoléin-4-yl)pyrazole-3-carboxamides substitués, procédé pour leur préparation et les compositions pharmaceutiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09761869 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009761869 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12993102 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0908627 Country of ref document: BR Kind code of ref document: A2 Effective date: 20101119 |